SNDX Syndax Pharmaceuticals, Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
Time
Author
Thesis
Company / ticker
Signal
Since call
Position
Source
21:44
Jan 18
Jan 18
r/biotech_stocks
SNDX revenue growth and EPS improvement toward 2026 profitability
The author estimates SNDX Q4 EPS at -0.53, improving from -0.70 in Q3 and -0.83 in Q2, with revenues expanding rapidly. Revuforj grew 38% quarter-over-quarter and Niktemvo revenue also increased, while the company has started two Phase 3 trials and partners are expanding drug labels. The author projects break-even or profitability by Q3 2026 and frames this as an attractive growth trajectory for a small biotech with one year of approved drugs.
SNDX
Syndax Pharmaceuticals, Inc.
Long
1ST
—
—
About SNDX Investor Commentary
Across the available history and selected sources, Buzzberg tracks SNDX (Syndax Pharmaceuticals, Inc.) across 5 sources: 1 bullish vs 0 bearish calls from 5 authors. Historical directional balance: 14% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 7 total trade ideas tracked. Latest voices: u/fbksminer.